These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma. Koppán M, Halmos G, Arencibia JM, Lamharzi N, Schally AV. Cancer; 1998 Oct 01; 83(7):1335-43. PubMed ID: 9762934 [Abstract] [Full Text] [Related]
6. Luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) and bombesin antagonist RC-3940-II inhibit the growth of androgen-independent PC-3 prostate cancer in nude mice. Jungwirth A, Galvan G, Pinski J, Halmos G, Szepeshazi K, Cai RZ, Groot K, Schally AV. Prostate; 1997 Aug 01; 32(3):164-72. PubMed ID: 9254895 [Abstract] [Full Text] [Related]
8. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ, Zarandi M. Prostate; 2005 Aug 01; 64(3):303-15. PubMed ID: 15754342 [Abstract] [Full Text] [Related]
9. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. Pinski J, Schally AV, Halmos G, Szepeshazi K. Int J Cancer; 1993 Dec 02; 55(6):963-7. PubMed ID: 7902829 [Abstract] [Full Text] [Related]
13. Inhibitory effects of antagonists of bombesin/gastrin releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, Milovanovic S, Miller G, Yano T. Acta Oncol; 1994 Dec 02; 33(6):693-701. PubMed ID: 7946450 [Abstract] [Full Text] [Related]
16. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K. Prostate; 2000 Jul 01; 44(2):172-80. PubMed ID: 10881027 [Abstract] [Full Text] [Related]
17. Inhibition of growth of OV-1063 human epithelial ovarian cancers and c- jun and c- fos oncogene expression by bombesin antagonists. Chatzistamou I, Schally AV, Sun B, Armatis P, Szepeshazi K. Br J Cancer; 2000 Oct 01; 83(7):906-13. PubMed ID: 10970693 [Abstract] [Full Text] [Related]
18. A single in vivo administration of bombesin antagonist RC-3095 reduces the levels and mRNA expression of epidermal growth factor receptors in MXT mouse mammary cancers. Szepeshazi K, Schally AV, Halmos G, Lamharzi N, Groot K, Horvath JE. Proc Natl Acad Sci U S A; 1997 Sep 30; 94(20):10913-8. PubMed ID: 9380734 [Abstract] [Full Text] [Related]
19. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Rick FG, Buchholz S, Schally AV, Szalontay L, Krishan A, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F. Cell Cycle; 2012 Jul 01; 11(13):2518-25. PubMed ID: 22751419 [Abstract] [Full Text] [Related]
20. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice. Yano T, Pinski J, Szepeshazi K, Halmos G, Radulovic S, Groot K, Schally AV. Cancer; 1994 Feb 15; 73(4):1229-38. PubMed ID: 8313327 [Abstract] [Full Text] [Related] Page: [Next] [New Search]